Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Non-Current Liabilities: 2019-2024

Historic Total Non-Current Liabilities for Fulcrum Therapeutics (FULC) over the last 4 years, with Dec 2024 value amounting to $17.5 million.

  • Fulcrum Therapeutics' Total Non-Current Liabilities fell 24.28% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year decrease of 24.28%. This contributed to the annual value of $17.5 million for FY2024, which is 21.60% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Total Non-Current Liabilities stood at $17.5 million for FY2024, which was down 21.60% from $22.3 million recorded in FY2023.
  • Fulcrum Therapeutics' Total Non-Current Liabilities' 5-year high stood at $27.5 million during FY2022, with a 5-year trough of $17.5 million in FY2024.
  • Over the past 3 years, Fulcrum Therapeutics' median Total Non-Current Liabilities value was $22.3 million (recorded in 2023), while the average stood at $22.4 million.
  • Data for Fulcrum Therapeutics' Total Non-Current Liabilities shows a maximum YoY fell of 21.60% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Fulcrum Therapeutics' Total Non-Current Liabilities stood at $27.5 million in 2022, then fell by 19.03% to $22.3 million in 2023, then declined by 21.60% to $17.5 million in 2024.